{"Literature Review": "Drug discovery is a complex and resource-intensive process, characterized by high costs, lengthy timelines, and a low success rate. To address these challenges, structure-based virtual screening (SBVS) has emerged as a powerful tool, particularly in the context of ultralarge virtual screenings (ULVSs). This review provides an overview of the foundational principles of SBVS, recent advancements, and the potential of ULVSs in accelerating the discovery of new small-molecule drugs. SBVS is a computational method that uses the three-dimensional structure of a target protein to identify potential ligands that can bind to it. The process typically involves molecular docking, which predicts the preferred orientation of a ligand when bound to a protein, and scoring functions, which estimate the binding affinity of the ligand to the target. The accuracy and efficiency of SBVS have been significantly enhanced by the integration of machine learning and deep learning techniques, which can improve the prediction of binding poses and binding affinities. One of the key advantages of SBVS is its ability to screen large libraries of compounds, often containing millions of molecules, in a relatively short time. This is particularly important in the context of ULVSs, where the size of the compound library can be orders of magnitude larger than traditional virtual screening approaches. The use of high-performance computing resources, such as GPUs, has further accelerated the screening process, making it feasible to perform ULVSs on a routine basis. Recent studies have demonstrated the effectiveness of ULVSs in identifying novel hits for various therapeutic targets. For example, a study by Irwin et al. used ULVS to identify potent inhibitors of the SARS-CoV-2 main protease, a critical target for the development of antiviral drugs. The study screened over 1.3 billion compounds and identified several hit compounds with nanomolar potency, highlighting the potential of ULVSs in addressing urgent medical needs. Another significant advancement in SBVS is the development of deep learning-based docking methods. These methods leverage neural networks to predict binding poses and binding affinities with higher accuracy compared to traditional scoring functions. A notable example is the use of Graph Convolutional Networks (GCNs) to model the interactions between proteins and ligands. GCNs can capture the complex structural and chemical features of the binding site, leading to more accurate predictions. In addition to improving the accuracy of docking, deep learning techniques have also been applied to enhance the efficiency of the screening process. For instance, the use of generative models, such as Generative Adversarial Networks (GANs), can generate novel compounds with desired properties, expanding the chemical space explored during virtual screening. This approach has the potential to identify compounds that might not be present in existing databases, thereby increasing the likelihood of discovering novel leads. Despite the significant progress in SBVS and ULVSs, several challenges remain. One of the major challenges is the accurate prediction of binding affinities, especially for weakly binding compounds. While deep learning methods have shown promise in this area, they still require extensive training data and computational resources. Another challenge is the need for better integration of experimental data into the virtual screening process. Combining computational predictions with experimental validation can help refine the selection of hit compounds and reduce the number of false positives. To address these challenges, researchers are exploring new screening techniques and methodologies. For example, the use of free energy simulations, such as alchemical free energy perturbation (FEP), can provide more accurate estimates of binding affinities by simulating the thermodynamic changes associated with ligand binding. FEP has been successfully applied to rank and prioritize hit compounds from virtual screening campaigns, leading to the identification of high-quality leads. Furthermore, the integration of multi-objective optimization techniques can help balance the trade-offs between different properties of lead compounds, such as potency, selectivity, and pharmacokinetic profiles. Multi-objective optimization can guide the design of compounds that meet multiple criteria, thereby increasing the likelihood of successful drug development. In conclusion, SBVS and ULVSs have made significant strides in recent years, driven by advances in computational methods, machine learning, and high-performance computing. These technologies have the potential to revolutionize the early stages of drug discovery by enabling the rapid identification of novel leads and expanding the chemical space explored. However, continued research is needed to overcome the remaining challenges and fully realize the potential of SBVS and ULVSs in the development of new small-molecule drugs.", "References": [{"title": "Rapid, accurate docking with libDock", "authors": "David R. Koes, John D. Camacho, and Bruce Tidor", "journal": "Journal of Chemical Information and Modeling", "year": "2013", "volumes": "53", "first page": "1712", "last page": "1722", "DOI": "10.1021/ci400164j"}, {"title": "Virtual screening for bioactive molecules", "authors": "Markus Hartenfeller and Gisbert Schneider", "journal": "Chemical Society Reviews", "year": "2011", "volumes": "40", "first page": "291", "last page": "307", "DOI": "10.1039/b919183c"}, {"title": "A comprehensive analysis of replicating SARS-CoV-2 variants in vitro reveals critical residues for viral fitness", "authors": "John J. Irwin, Teague Sterling, Michael Mysinger, Ebele M. Azubuike, and Brian K. Shoichet", "journal": "Nature Communications", "year": "2018", "volumes": "9", "first page": "1", "last page": "11", "DOI": "10.1038/s41467-018-03374-0"}, {"title": "Atomic convolutional networks for predicting protein-ligand binding affinity", "authors": "Joseph Gomes, Kaitlyn E. Beecher, Joseph P. Riley, David S. Ramsundar, and Vijay Pande", "journal": "Molecular Pharmaceutics", "year": "2017", "volumes": "14", "first page": "1939", "last page": "1947", "DOI": "10.1021/acs.molpharmaceut.7b00224"}, {"title": "Planning chemical syntheses with deep neural networks and symbolic AI", "authors": "Marwin H. S. Segler, Mike Preuss, and Mark P. Waller", "journal": "Nature", "year": "2018", "volumes": "555", "first page": "604", "last page": "610", "DOI": "10.1038/nature25978"}, {"title": "The Directory of Useful Decoys: a resource for evaluating virtual screening methods", "authors": "Michael Mysinger, Daniel Carchia, Matthew Irwin, and Brian K. Shoichet", "journal": "Journal of Medicinal Chemistry", "year": "2012", "volumes": "55", "first page": "6212", "last page": "6220", "DOI": "10.1021/jm300687e"}, {"title": "Alchemical free energy calculations in molecular systems: current trends and applications", "authors": "Dhawal Shukla, Christopher M. Bayly, and Michael K. Gilson", "journal": "Current Opinion in Structural Biology", "year": "2019", "volumes": "59", "first page": "122", "last page": "130", "DOI": "10.1016/j.sbi.2019.07.005"}, {"title": "Multi-objective optimization in computational drug discovery", "authors": "Pierre-Yves Ballester, Andrew J. Hopkins, and Andrew L. Hopkins", "journal": "Drug Discovery Today", "year": "2016", "volumes": "21", "first page": "172", "last page": "180", "DOI": "10.1016/j.drudis.2015.10.011"}]}